Caris Life Sciences to present CapeAI study predicting capecitabine response in ER+ breast cancer at ESMO 2026
Caris Life Sciences flagged eight AI-driven precision-oncology studies slated for presentation at the ESMO Congress 2026 in Madrid. Results have not yet been presented; posters are scheduled for Oct. 23—27, 2026, with Caris-led sessions on Oct. 25. Two Caris-led studies aim to improve breast-cancer treatment selection